OBJECTIVE: These studies were designed to investigate the mechanism through which enterostatin inhibits insulin secretion from pancreatic islets. DESIGN: A static islet incubation method was used to study the effects of enterostatin on insulin secretion induced by various secretagogues and to investigate the effect of calcium ions and 8-Br-cyclic AMP on the response to enterostatin. Measurements of islet cAMP concentrations in response to enterostatin were also made. RESULTS: Enterostatin (10 79 to 10 75 M) inhibited insulin secretion from islets incubated in the presence of 16.7 mM glucose in a dose-dependent manner. Enterostatin also inhibited insulin secretion stimulated by glybenclamide (5.0 and 10 m mM), phorbol 12-myristate-13-acetate (TPA) (50 and 100 nM), and the kappa-opioid agonist U50,488 (100 nM). The inhibitory effect of enterostatin on TPA-induced insulin secretion was attenuated but still remained in the absence of extracellular Ca 2 . The enterostatin inhibition of insulin secretion was blocked by 8-Br-cAMP (1 mM) independent of extracellular Ca 2 . Enterostatin reduced the increase in intracellular cyclic AMP (cAMP) content produced by U50,488 (100 nM) and the changes in cAMP content were parallel with changes in insulin release. CONCLUSION: Enterostatin may suppress insulin secretion through the reduction of cAMP, but other mechanisms may also be possible.
Introduction
Enterostatin is the amino-terminal pentapeptide of procolipase, a 101 amino acid protein, synthesized in the exocrine pancreas 1 and gastric mucosa. 2 After pancreatic secretion has been stimulated by the presence of fat in the proximal duodenum, enterostatin is released from pancreatic procolipase by tryptic hydrolysis in the small intestine. 3 Colipase serves as an essential cofactor to enable pancreatic lipase to digest dietary triacylglycerols in the presence of bile salts. Enterostatin may act as a feedback signal to regulate fat intake andaor fat appetite. 4 Both peripheral and central administration of this peptide to rats has been shown to reduce food intake, and this reduction is selective towards dietary fat. 5 ± 9 Although no receptors have yet been identi®ed for enterostatin, its effects on fat intake appear to be expressed at both gastrointestinal and central sites. The response to peripheral enterostatin is mediated through the hepatic vagus, since both selective hepatic vagotomy and capsaicin treatment abolish the response. 10, 11 The central response to enterostatin appears to be expressed through a pathway containing both kopioidergic and serotonergic components. Kappaopioidergic agonists inhibit enterostatin feeding, whereas the K-opioidergic antagonist, nor-BNI, mimics the selective effect of enterostatin on fat intake. 12, 13 In contrast, the general serotonergic antagonist, metergoline, blocks the response to intracerebroventricular (icv) enterostatin. 14 In addition to its effects on food intake, enterostatin also appears to affect peripheral metabolism through activation of the sympathetic drive to stimulate brown adipose tissue thermogenesis 15 and through actions to inhibit insulin secretion 16 ± 18 and to stimulate corticosterone secretion. 17, 19, 20 Although several studies have shown that enterostatin inhibited insulin secretion in vivo, 17 ± 20 recent studies using either perifusion of isolated islets 16 or perfusion of the rat pancreas 21 have demonstrated that enterostatin directly inhibits insulin release from islet cells induced by either glucose, tolbutamide or arginine. However, the mechanism for this inhibition of insulin release by enterostatin was not identi®ed. The present study aims to gain insight into the mechanism by which enterostatin inhibits insulin secretion in freshly isolated islets from normal rats. We have investigated the putative intracellular signal transmission to enterostatin in a series of experiments designed to study the potential roles of the K -dependent ATPase, calcium ions, the adenylyl cyclase system, and the kappaopioid pathway.
Materials and methods

Material
Enterostatin (Val-Pro-Asp-Pro-Arg) was synthesized by the Biotechnology Core Laboratory of Louisiana State University (New Orleans, LA) and was shown to be 95% pure by HPLC. U-50,488, phorbol 12-myristate 13-acetate (TPA) and 8-bromo-cyclic AMP (cAMP) were purchased from Research Biochemical Incorporated (Natick, MA). Glybenclamide and 3-isobutyl-methylxanthine (IBMX) were purchased from Sigma (St Louis, MO). Ficol was purchased from Pharmacia (Piscataway, NJ), Collagenase type 4 from Worthington Biochemical Corporation (Freehold, NJ) and Conray was a gift from Dr Sakata (Oita University, Japan).
Isolation and incubation of islets of Langerhans
Islets were isolated from male Sprague-Dawley rats (8±12 weeks of age) by collagenase digestion, followed by collection using a Ficoll-Conray discontinuous gradient. 22, 23 Islets were maintained for 4.5 h in Eagle's MEM culture medium, containing 5.6 mM glucose and supplemented with 10% (vav) heatinactivated fetal bovine serum.
Measurements of insulin release
For measurements of insulin release, islets were preincubated in Hank's Balanced salt solution (HBSS) pH 7.4, supplemented with bovine serum albumin (BSA) (2 gal), and 3.3 mM glucose for 60 min at 37 C with or without enterostatin. Each incubation contained two islets in 200 ml HBSS. Subsequently, glucose andaor drugs were added and the incubation continued for a further 30 min at 37 C. Samples of the incubation medium were stored at 720 C until insulin levels were assayed by a rat radioimmunoassay system (Linco Research, Inc., MO ).
Measurements of cyclic AMP (cAMP)
Ten islets were preincubated for 50 min at 37 C with or without enterostatin. After 50 min 0.5 mM IBMX was added. At 60 min, islets were transferred into 200 ml HBSS containing test compounds and incubated at 37 C for 30 min. The incubation was stopped by adding 200 ml of ice-cold trichloroacetic acid (20%, wav). Islets were then sonicated and centrifuged for 15 min at 2000 g. The supernatant was recovered, washed four times with 2 ml of water-saturated diethyl ether and ®nally heated to 70 C to remove all the ether. The samples were then assayed for cAMP using a radioimmunoassay system (Amersham International, Amersham, UK).
Statistical analysis
All insulin secretion data were expressed as percent of insulin secretion under the basal (3.3 mM glucose) conditions. Data was analyzed by 2-or 3-way Analysis of Variance (ANOVA) using the program Stat View for Macintosh. Signi®cant differences between groups were assessed by the post-hoc test of BonnFerroni Dunn with 0.05 or 0.01 as signi®cant P values.
Results
Effect of enterostatin on high glucose stimulated insulin release
The dose-related effect of enterostatin on insulin release stimulated by 16.7 mM glucose, is shown in Figure 1 . One way ANOVA showed a signi®cant effect of enterostatin (F(5,65) 6.575, P`0.0001). The comparison between the treatment means, revealed that enterostatin signi®cantly suppressed glucose-induced insulin secretion, at concentrations from 10 79 M to10 75 M. Enterostatin did not signi®-cantly modify insulin secretion induced by either 3.3 mM or 5.6 mM of glucose (data not shown).
Effect of enterostatin on glybenclamide-induced insulin secretion
The effect of enterostatin on glybenclamide-induced insulin release, is shown in Figure 2 . Two-way ANOVA showed a signi®cant dose-related effect of glybenclamide (F(1,33) 4.14, P`0.05) and a suppressive effect of enterostatin on glybenclamide-induced insulin secretion (F(2,33) 18.75, P`0.0001). Enterostatin reduced insulin secretion to similar levels at both glybenclamide concentrations used.
Effect of enterostatin on phorbol ester (TPA)-stimulated insulin secretion
The effect of enterostatin on TPA-induced insulin secretion in either the presence or absence of Ca 2 is shown in Figure 3 . Three way ANOVA showed signi®cant effects of enterostatin (F(2,75) 55.69, P`0.001) and Ca 2 (F(1,75) 12.10, P`0.001). Post-hoc tests revealed that both 0.1 and 1.0 mM Enterostatin and insulin secretion M Ookuma and DA York enterostatin signi®cantly suppressed insulin release in response to TPA (100 nM) (P`0.01). In the absence of Ca 2 , comparison of treatment means, revealed that enterostatin was only effective at a concentration of 1.0 mM (P`0.01).
Effect of enterostatin on TPA-induced insulin secretion and its modulation by additional 8-Br-cAMP in the presence or absence of Ca , enterostatin (0.1 and 1.0 mM) signi®cantly inhibited the TPA (50 nM)-induced insulin secretion again (P`0.01) and this inhibition was completely abolished by 8-Br-cAMP. 8-Br-cAMP alone caused a small increase in TPA-induced insulin secretion but this effect was far smaller than the reversal of the enterostatin inhibitory effect. TPA-induced insulin secretion was lowered in the absence of extracellular Ca 2 (P`0.05). In this condition, only the higher (1.0 mM) concentration of enterostatin suppressed TPA-induced insulin secretion (P`0.01), but this inhibition was also completely abolished by 8-BrcAMP.
Effects of enterostatin on insulin release and c-AMP production induced by the kappa-opioid agonist U50,488
The effect of enterostatin on U50,488-induced insulin release and islet cAMP content is shown in Figure 5 . In this experiment 5.6 mM glucose was used rather than 3.3 mM glucose, to promote a higher level of cAMP production for assay. One way-ANOVA . Islets were incubated in Hank's balanced salt solution (HBSS) containing glucose (3.3 mM) and TPA (100 nM) and enterostatin (0.1 or 1.0 mM) for 30 min at 37 C. Identical experiments were repeated in calcium-free buffer supplemented with 500 mM EGTA. At least six incubations were included in each group. Data represent mean AE s.e.m. Basal insulin secretion (100%) assayed in the presence of 3.3 mM glucose and the absence of TPA was 1.29 AE 0.06 and 1.11 AE 0.15 ngaml in calcium containing and calcium-free media, respectively. *P`0.05; **P`0.01 compared to glucose-stimulated values in the absence of enterostatin. 
Discussion
Recent studies using either perifusion of isolated islets 16 or perfusion of the rat pancreas 21 have demonstrated that enterostatin directly inhibits insulin release induced by either glucose, tolbutamide or arginine. In the present study, enterostatin at the concentration of 10 79 ±10 75 M also inhibited insulin secretion stimulated by 16.7 mM glucose in isolated normal rat islets using a static batch incubation method. The range of effective concentrations was lower than that identi®ed in the previous reports, in which the lowest concentration used was 100 nM. Interestingly, despite the wide range of enterostatin doses used, there was no indication of the U-shaped dose-response curve that is evident in its effects on food intake.
9,24
Enterostatin appears to inhibit both ®rst phase and second-phase insulin secretion, 16, 21 in response to both glucose and tolbutamide. In the present study, we observed that enterostatin inhibited glybenclamide-induced insulin release. Sulphonylureas bind to plasma membrane receptors on the B-cell. 25 Following binding, K ef¯ux through ATP-sensitive K channel decreases, causing cell depolarization and subsequent in¯ux of Ca 2 . Thus, the suppressive effect of enterostatin on glybenclamide-induced insulin secretion, was consistent with an enterostatin effect on the ®rst phase of insulin secretion.
TPA has been reported to induce insulin secretion from isolated islets 26 and insulinoma cells, 27 by activating islet protein kinase C in vitro. The action of TPA on insulin secretion is slowly evolving, but sustained. In the present experiments, TPA potently stimulated insulin secretion con®rming previous reports. 26, 28 This stimulation was signi®cantly attenuated by enterostatin, suggesting that enterostatin inhibits the action of protein kinase C. This inhibitory effect was also observed in the absence of Ca 2 , suggesting that enterostatin acts through a mechanism that is independent of the hyperpolarization of the B-cell membrane. Activation of PKC has been associated with the development of insulin resistance. 29 While there have not yet been any direct studies on the effects of enterostatin on insulin sensitivity, the observations that enterostatin reduces serum insulin without effecting blood glucose, 17 ± 19 suggest that it improves insulin sensitivity. This would be consistent with the current data, which suggests that enterostatin inhibits PKC activity.
The cAMP stimulation of insulin release appears to be independent of calcium, 30 as is the enterostatin inhibition of insulin release. To investigate the possibility that cAMP activity is involved in the action of enterostatin on insulin secretion, we examined whether cAMP could inhibit the suppressive effect of enterostatin on TPA-induced insulin secretion. The present results showed that the enterostatin inhibition of TPA-induced insulin release was completely reversed by 1 mM 8-Br-cAMP. Furthermore, this effect of 8-Br-cAMP was evident in the absence of extracellular Ca 2 . It is possible that 8-Br-cAMP could overcome the effects of inhibitory agents that do not act by inhibition of adenylyl cyclase. However, the observations that enterostatin could reduce islet cAMP concentrations induced by U50,488 and that 8-Br-cAMP overcame the enterostatin inhibition of TPA-induced insulin secretion suggest that C. Either insulin release (A, n 9) or cAMP content (B, n 6) was measured. Data represent mean AE s.e.m. Basal insulin secretion (100%) assayed in buffer containing 5.6 mM glucose alone was 920 AE 117 fmolesa10 islets. *P`0.05, **P`0.01 compared to glucose-stimulated values in the absence of enterostatin.
Enterostatin and insulin secretion M Ookuma and DA York enterostatin may inhibit insulin secretion by decreasing cAMP content, independent of Ca 2 . Opioids effect glucose metabolism 31 through either direct actions on the pancreas 32 or through centrally mediated autonomic effects. 33 Opioid receptors are found on the membranous surface of beta cells. 34 Opioid peptides are known to prime the pancreas islets by raising cAMP, facilitating a greater response to subsequent stimulation by nutritional and other factors in vivo. 35 On the other hand, opioids are also involved in the central regulation of food intake, 12, 13, 36 and the pathway through which enterostatin inhibits fat intake is known to have a kappa-opioid component. 12, 13 The kappa-opioid agonist U50,488 reverses 12 and the kappa-antagonist nor-binaltorphimine synergistically 13 increases the enterostatin effects on fat intake. These observations suggested the possibility that enterostatin might similarly modulate a kappa-opioid system in the b-cell to inhibit insulin secretion. Our data supported this hypothesis. The stimulation of insulin release by the kappa-opioid agonist U50,488 was completely abolished by both 0.1 and 1.0 mM enterostatin. It was particularly noteworthy that the cAMP content in the islet cells showed parallel changes with the insulin secretory responses to the treatments. The cAMP level was increased by U50,488 and the increase was completely reversed by either 0.1 or 1.0 mM of enterostatin. These ®ndings, together with the ability to overcome the enterostatin effect with 8-Br-cAMP, suggest that enterostatin modulates its effect on insulin secretion by reduction of cAMP content in the b-cells.
Our data have shown that enterostatin inhibits induced insulin secretion from normal rat islets incubated with various secretory stimuli including glucose, glybenclamide, TPA and U50,488. It further suggests that enterostatin may inhibit both TPAinduced and U50,488-induced insulin secretion through its effects on cAMP. However, we cannot yet be sure that this is the only mechanism through which enterostatin effects insulin secretion. In particular, glucose-induced insulin secretion does not require any increase in cAMP levels. 37 In this case, it is possible either that enterostatin inhibits insulin through an alternative mechanism or that it reduces cAMP below levels which are essential for normal b-cell responsiveness to glucose. 38 Further experiments will be required to clarify these possibilities.
